Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of HK010 injection in PD-L1 positive advanced solid tumors
CTR20254818Phase 2Active
- Sponsor
- Anke Bio
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HK010 in hepatocellular carcinoma (HCC), extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Anke Bio. Started Jan 2026; status: active.
02
Drugs
HK010
03
Conditions
hepatocellular carcinoma (HCC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on CTR20254818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254818.